Company Profile

Cipla has reported results for the fourth quarter and year ended March 31, 2020.

The Company has reported a fall of 4.65% in its net profit at Rs 604.57 crore for the quarter under review as compared to Rs 634.07 crore for the same quarter in the previous year. Total income of the company decreased by 0.11% at Rs 3546.85 crore for Q4FY20 as compared Rs 3550.92 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 33.02% in its net profit attributable to shareholders of the company of Rs 245.95 crore for the quarter under review as compared to Rs 367.20 crore for the same quarter in the previous year. Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20 as compared Rs 4499.34 crore for the corresponding quarter previous year.

For the year ended March 31, 2020, the company has reported a rise of 22.76% in its net profit at Rs 2318.17 crore as compared to Rs 1888.41 crore for the previous year. Total income of the company increased by 4.64% at Rs 13552.00 crore for year under review as compared to Rs 12951.53 crore for year ended March 31, 2019.

For the year ended March 31, 2020, on the consolidated basis, the company has reported a rise of 1.23% in its net profit attributable to shareholders of the company of Rs 1546.52 crore as compared to Rs 1527.70 crore for the previous year. Total income of the company increased by 3.78% at Rs 17476.19 crore for year under review as compared to Rs 16838.98 crore for year ended March 31, 2019.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a Competitive Generic Therapy (CGT) designation. The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product. This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

The company's Dihydroergotamine Mesylate Nasal Spray 4mg/mL is AB-rated generic therapeutic equivalent version of Bausch Health US LLC’s Migranal. This is company’s first ANDA approval for a nasal spray. It is indicated for the acute treatment of migraine headaches with or without aura. According to IQVIA (IMS Health), Migranal and its authorized generic equivalents had U.S. sales of approximately $102M for the 12-month period ending March 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 624.20, up by 3.85 points or 0.62% from its previous closing of Rs. 620.35 on the BSE.

The scrip opened at Rs. 620.15 and has touched a high and low of Rs. 626.60 and Rs. 617.00 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 632.05 on 27-Apr-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 626.60 and Rs. 565.90 respectively. The current market cap of the company is Rs. 50015.05 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a Competitive Generic Therapy (CGT) designation. The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product. This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

The company's Dihydroergotamine Mesylate Nasal Spray 4mg/mL is AB-rated generic therapeutic equivalent version of Bausch Health US LLC’s Migranal. This is company’s first ANDA approval for a nasal spray. It is indicated for the acute treatment of migraine headaches with or without aura. According to IQVIA (IMS Health), Migranal and its authorized generic equivalents had U.S. sales of approximately $102M for the 12-month period ending March 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a Competitive Generic Therapy (CGT) designation. The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product. This 180-day CGT exclusivity will not block the commercialization of the existing approvals of Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL.

Tata Power Company’s wholly owned subsidiary---Tata Power International (TPIPL) has acquired 10% equity stake Adjaristqali Netherlands B.V. (ABV) from International Finance Corporation (IFC) for a sum of $150,000. This acquisition has been done as per the provisions of the shareholder agreement. Post this acquisition, the company, through TPIPL, holds 50% stake in ABV.

Natco Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India, for an inspection conducted during the period from March 24 to March 30, 2020.

Adani Enterprises has raised Rs. 400 crore by allotment of 4,000 Rated, Listed Secured Redeemable Non-Convertible Debentures (NCDs) of the face value of Rs. 10,00,000 each on private placement basis. The said NCDs will be listed on the Wholesale Debt Market segment of BSE.

Finolex Industries has increased the Turnover Discount Scheme (TOD) across its dealer network which is in addition to the TOD that the company pays to incentivise its dealer network. This was the result of week-long deliberations that the company had with its dedicated network of dealers and employees based across the country. The company has a network of over 18,000 retailers, dealers and sub-dealers.

Crompton Greaves Consumer Electricals’ Committee of Debentures have inter alia, approved the pricing, tenure and other terms and conditions for issuance of 3,000 listed, secured, rated, redeemable, non-convertible debenture (NCDs) of Rs 10,00,000 aggregating to Rs 300 crore each on Private Placement basis. NCDs will be for three years from the deemed date of allotment, which is May 28, 2020 and will be listed on the NSE.

Reliance Industries has raised Rs 3,600 crore (PPD Series N Debentures) and allotted 36,000 Unsecured Redeemable Non-Convertible Debentures (NCDs) of the face value of Rs 10 lakh each, issued on private placement basis on May 19, 2020.

Cipla has submitted an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the United States Food and Drug Administration (USFDA). The company had recently announced the successful completion of its Phase-3 clinical end-point study for the product in the first attempt.

The product is the generic version of GSK’s Advair Diskus. According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of approximately $2.9bn for the 12-month period ending March 2020. It is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older. It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.